Regulation of plasminogen receptor expression on human monocytes and monocytoid cell lines

The capacity of human monocytoid cell lines and peripheral blood monocytes to modulate their expression of plasminogen receptors has been assessed. After PMA stimulation, THP-1 or U937 monocytoid cells were separated into adherent and nonadherent populations. Plasminogen bound to adherent cells with similar capacity and affinity as to nonstimulated cells. In contrast, the nonadherent cells bound plasminogen with 5-17-fold higher capacity (without a change in affinity). This increase was selective as urokinase bound with similar affinity and capacity to the adherent and nonadherent populations. Upregulation of plasminogen receptors on the nonadherent monocytoid cells was rapid, detectable within 30 min, and reversible, adhesion of the nonadherent cells resulted in a sixfold decrease in plasminogen binding within 90 min. The increase in plasminogen binding to the nonadherent cells was associated with a marked increase in their capacity to generate plasmin activity from cell-bound plasminogen. PMA stimulation of human peripheral blood monocytes increased their expression of plasminogen receptors by two- to fourfold. This increase was observed in both adherent and nonadherent monocytes. Freshly isolated monocytes maximally bound 5.0 x 10(5) plasminogen molecules per cell, whereas monocytes cultured for 18 h or more maximally bound 1.7 x 10(7) molecules per cell, a 30-fold difference in receptor number. These results indicate that both monocytes and monocytoid cell lines can rapidly and markedly regulate their expression of plasminogen binding sites. As enhanced plasminogen binding is correlated with an increased capacity to generate plasmin, an enzyme with broad substrate recognition, modulation of plasminogen receptors may have profound functional consequences.

[1]  Diana,et al.  plasminogen activator Interleukin-4 stimulates human monocytes to produce tissue-type , 2005 .

[2]  T. Reilly,et al.  Binding of Tissue Plasminogen Activator to Cultured Human Fibroblasts , 1989, Thrombosis and Haemostasis.

[3]  P. Hart,et al.  Human monocytes can produce tissue-type plasminogen activator , 1989, The Journal of experimental medicine.

[4]  P. Burtin,et al.  Limited proteolysis of tumor cells increases their plasmin‐binding ability , 1989, FEBS letters.

[5]  M. Cubellis,et al.  Regulation of urokinase receptors in monocytelike U937 cells by phorbol ester phorbol myristate acetate , 1989, The Journal of cell biology.

[6]  D. Belin,et al.  Characterization of the cellular binding site for the urokinase-type plasminogen activator. , 1989, The Journal of biological chemistry.

[7]  H. Remold,et al.  IFN-gamma, tumor necrosis factor-alpha, and urokinase regulate the expression of urokinase receptors on human monocytes. , 1988, Journal of immunology.

[8]  R. Silverstein,et al.  Binding of Lys-plasminogen to monocytes/macrophages. , 1988, The Journal of clinical investigation.

[9]  K. Hajjar,et al.  Endothelial cell-mediated conversion of Glu-plasminogen to Lys-plasminogen. Further evidence for assembly of the fibrinolytic system on the endothelial cell surface. , 1988, The Journal of clinical investigation.

[10]  J. Soria,et al.  Parallel induction of fibrinolysis and receptors for plasminogen and urokinase by interferon gamma on U937 cells. , 1988, Biochemical and biophysical research communications.

[11]  E. Plow,et al.  The cell-binding domains of plasminogen and their function in plasma. , 1988, The Journal of biological chemistry.

[12]  D. Rifkin,et al.  Membrane and matrix localization of proteinases: a common theme in tumor cell invasion and angiogenesis. , 1988, Biochimica et biophysica acta.

[13]  J. Plescia,et al.  Plasminogen receptors, urokinase receptors, and their modulation on human endothelial cells. , 1988, Blood.

[14]  P. Burtin,et al.  Receptor for plasmin on human carcinoma cells. , 1988, Journal of the National Cancer Institute.

[15]  J. Fantone,et al.  Rapid purification of human peripheral blood monocytes by centrifugation through Ficoll-Hypaque and Sepracell-MN. , 1988, Journal of immunological methods.

[16]  D. Cines,et al.  Tissue-type plasminogen activator binding to human endothelial cells. Evidence for two distinct binding sites. , 1988, The Journal of biological chemistry.

[17]  E. Plow,et al.  Plasminogen receptors: Ubiquitous sites for cellular regulation of fibrinolysis , 1988 .

[18]  J. Weinberg,et al.  Cooperative effect of tumor necrosis factor and gamma-interferon on chemotactic peptide receptor expression and stimulus-induced actin polymerization in HL-60 cells. , 1988, Blood.

[19]  F. Blasi Surface Receptors for Urokinase Plasminogen Activator , 1988 .

[20]  Volker Herzog,et al.  Establishment of a human cell line (mono mac 6) with characteristics of mature monocytes , 1988, International journal of cancer.

[21]  S. Haskill,et al.  Adherence induces selective mRNA expression of monocyte mediators and proto-oncogenes. , 1988, Journal of immunology.

[22]  T. Okazaki,et al.  Evidence of intracellular and trans‐acting differentiation‐inducing activity in human promyelocytic leukemia HL‐60 cells: Its possible involvement in process of cell differentiation from a commitment step to a phenotype‐expression step , 1988, Journal of cellular physiology.

[23]  K. Hajjar,et al.  Binding of tissue plasminogen activator to cultured human endothelial cells. , 1987, The Journal of clinical investigation.

[24]  E. Plow,et al.  Receptor Mediated Binding of the Fibrinolytic Components, Plasminogen and Urokinase, to Peripheral Blood Cells , 1987, Thrombosis and Haemostasis.

[25]  J. Larrick,et al.  Receptor-mediated monocytoid differentiation of human promyelocytic cells by tumor necrosis factor: synergistic actions with interferon-gamma and 1,25-dihydroxyvitamin D3. , 1987, Blood.

[26]  S. Krane,et al.  1,25-Dihydroxyvitamin D3 induces collagen binding to the human monocyte line U937. , 1987, The Journal of clinical investigation.

[27]  D. Belin,et al.  Plasminogen activator-specific inhibitors in mouse macrophages: in vivo and in vitro modulation of their synthesis and secretion. , 1987, Journal of immunology.

[28]  P. Johnston,et al.  Expression of a 120,000 dalton protein during tumoricidal activation in murine peritoneal macrophages. , 1987, Journal of immunology.

[29]  D. Beebe Binding of tissue plasminogen activator to human umbilical vein endothelial cells. , 1987, Thrombosis research.

[30]  J. Plescia,et al.  The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type , 1986, The Journal of cell biology.

[31]  E. Jaffe,et al.  Binding of plasminogen to cultured human endothelial cells. , 1986, The Journal of biological chemistry.

[32]  J. White,et al.  Plasminogen interacts with human platelets through two distinct mechanisms. , 1986, The Journal of clinical investigation.

[33]  H. Young,et al.  Intracellular localization of human monocyte associated interleukin 1 (IL 1) activity and release of biologically active IL 1 from monocytes by trypsin and plasmin. , 1986, Journal of immunology.

[34]  J. Baker,et al.  Cryptic urokinase binding sites on human foreskin fibroblasts. , 1985, Biochemical and biophysical research communications.

[35]  S. Gregory,et al.  Tissue factor induction in human monocytes. Two distinct mechanisms displayed by different alloantigen-responsive T cell clones. , 1985, The Journal of clinical investigation.

[36]  H. Chapman,et al.  Characterization of a macrophage-derived plasminogen-activator inhibitor. Similarities with placental urokinase inhibitor. , 1985, Biochemical Journal.

[37]  A. Corti,et al.  Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[38]  E. Plow,et al.  Binding and activation of plasminogen on the platelet surface. , 1985, The Journal of biological chemistry.

[39]  G. Dini,et al.  Receptors for plasminogen activator, urokinase, in normal and Rous sarcoma virus-transformed mouse fibroblasts. , 1985, Cancer research.

[40]  D. Belin,et al.  A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase , 1985, The Journal of cell biology.

[41]  D. Belin,et al.  Concomitant secretion of prourokinase and of a plasminogen activator- specific inhibitor by cultured human monocytes-macrophages , 1984, The Journal of experimental medicine.

[42]  R. Schreiber,et al.  Anti-mac-1 Selectively Inhibits the Mouse and Human Type Three Complement Receptor* , 2003 .

[43]  K. Tada,et al.  Induction of maturation in cultured human monocytic leukemia cells by a phorbol diester. , 1982, Cancer research.

[44]  M. Mosesson,et al.  Receptors for cold-insoluble globulin (plasma fibronectin) on human monocytes , 1981, The Journal of experimental medicine.

[45]  D Rodbard,et al.  Ligand: a versatile computerized approach for characterization of ligand-binding systems. , 1980, Analytical biochemistry.

[46]  Shigeru Tsuchiya,et al.  Establishment and characterization of a human acute monocytic leukemia cell line (THP‐1) , 1980, International journal of cancer.

[47]  M. Ferrarini,et al.  Ultrastructure and cytochemistry of human peripheral blood lymphocytes. Similarities between the cells of the third population and TG lymphocytes , 1980, European journal of immunology.

[48]  S. Collins,et al.  Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[49]  T. Edgington,et al.  Lymphocyte cooperation is required for amplification of macrophage procoagulant activity , 1980, The Journal of experimental medicine.

[50]  J. Goding Conjugation of antibodies with fluorochromes: modifications to the standard methods. , 1976, Journal of immunological methods.

[51]  L. Holmberg,et al.  Purification of urokinase by affinity chromatography. , 1976, Biochimica et biophysica acta.

[52]  J. Vassalli,et al.  Macrophage plasminogen activator: Modulation of enzyme production by anti-inflammatory steroids, mitotic inhibitors, and cyclic nucleotides , 1976, Cell.

[53]  B. Wiman,et al.  Characterization of human plasminogen. II. Separation and partial characterization of different molecular forms of human plasminogen. , 1972, Biochimica et biophysica acta.

[54]  D. Deutsch,et al.  Plasminogen: Purification from Human Plasma by Affinity Chromatography , 1970, Science.

[55]  B. Wiman,et al.  Characterization of human plasminogen. I. On the relationship between different molecular forms of plasminogen demonstrated in plasma and found in purified preparations. , 1970, Biochimica et biophysica acta.

[56]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[57]  T. The,et al.  Conjugation of fluorescein isothiocyanate to antibodies. I. Experiments on the conditions of conjugation. , 1970, Immunology.

[58]  K. Weber,et al.  The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis. , 1969, The Journal of biological chemistry.

[59]  S. Müllertz ACTIVATION OF PLASMINOGEN , 1957 .

[60]  J. Soria,et al.  Enhanced expression of urokinase activity on U 937 cell line by 1,25-dihydroxyvitamin D3 induction. , 1988, Thrombosis research. Supplement.

[61]  S. Bajaj,et al.  Expression of tissue factor and factor VIIa/tissue factor inhibitor activity in endotoxin or phorbol ester stimulated U937 monocyte-like cells. , 1988, Blood.

[62]  K. Danø,et al.  Plasminogen activators, tissue degradation, and cancer. , 1985, Advances in cancer research.

[63]  E. Reich ACTIVATION OF PLASMINOGEN: A GENERAL MECHANISM FOR PRODUCING LOCALIZED EXTRACELLULAR PROTEOLYSIS , 1978 .

[64]  S. Krane,et al.  1 , 25-Dihydroxyvitamin D 3 Induces Collagen Binding to the Human Monocyte Line U 937 , 2022 .